Clinical Trial Update: Phase 1 Safety Study of ALRN-5281 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 safety study of ALRN-5281 in healthy subjects has been completed, reporting safety and tolerability data from volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• ALRN-5281

Snippet

Sponsor: Aileron Therapeutics, Inc. | Conditions: Growth Hormone Deficiency | Phase 1 | Status: COMPLETED